7C8 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.07
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€2.71M
Enterprise Value€4.42
Total Cash (Recent Filing)€592.31K
Total Debt (Recent Filing)€1.55M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding109,200,640
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.17
P/FCF Ratio-1.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology Therapy PipelineA focused photodynamic therapy platform gives Invion a defined route to develop oncology treatments across breast and gastrointestinal indications, with potential long-term value if clinical development supports partnering or commercialisation.
Moderate Balance Sheet LeverageDebt is not currently the primary balance-sheet constraint, leaving the company with more manageable leverage than a highly debt-funded biotech. This provides some financial flexibility while development activities continue, despite broader capital pressures.
Positive Gross Profit In 2026Positive gross profit indicates that some revenue-generating activity can exceed direct costs, providing a potential foundation for improvement if revenue becomes more consistent. However, this remains insufficient to offset the company’s broader operating cost base.
Bears Say
Persistent Losses And Unstable RevenueRepeated losses and a sharply contracted revenue base indicate that Invion has not established a stable commercial engine. This weakens earnings visibility and leaves future progress dependent on successful development, funding, or partnership outcomes.
Ongoing Operating Cash BurnSustained negative operating and free cash flow means the business is not self-funding its activities. Continued cash consumption may require additional capital, potentially limiting development pace and increasing financing or dilution risk over the medium term.
Material Equity ErosionThe steep reduction in equity reflects the cumulative impact of losses and capital consumption. It reduces the company’s financial buffer and increases dependence on external funding, making shareholders more exposed to dilution and execution risk.
Invion News
7C8 FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was €0.02 and its highest was €0.07 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is €2.71M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Feb 24, 2027 which is in 168 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Aug 27, 2026. The company reported -€0.013 earnings per share for the quarter.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -€0.013 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in DE:7C8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―